The mAb against adipocyte fatty acid-binding protein 2E4 attenuates the inflammation in the mouse model of high-fat diet-induced obesity via toll-like receptor 4 pathway

Molecular and Cellular Endocrinology

Volumn 403, Issue , 2015, Pages 1-9

  Miao, Xiaoliang ^a   Wang, Ying ^a   Wang, Wang ^a   Lv, Xiaobo ^a   Wang, Min ^a   Yin, Hongping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Adipocyte fatty acid binding protein; Inflammation; Monoclonal antibody 2E4; Toll like receptor 4

Indexed keywords

CHOLESTEROL; CYTOKINE; FATTY ACID; FATTY ACID BINDING PROTEIN 4; GLUCOSE; INTERLEUKIN 6; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIOBESITY AGENT; CCL2 PROTEIN, MOUSE; FABP4 PROTEIN, MOUSE; FAT INTAKE; FATTY ACID BINDING PROTEIN; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; TLR4 PROTEIN, MOUSE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID BLOOD LEVEL; INFLAMMATION; LIPID DIET; METABOLISM; MOUSE; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOCYTE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FAT INTAKE; FEMALE; GENE EXPRESSION; GENETICS; MOUSE MUTANT; PATHOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; ANTIBODIES, MONOCLONAL; CHEMOKINE CCL2; CHOLESTEROL; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, NONESTERIFIED; FEMALE; GENE EXPRESSION; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921535523     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.12.017     Document Type: Article

References (51)

1. Baar R.A., Dingfelder C.S., Smith L.A., Bernlohr D.A., Wu C., Lange A.J., et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice. Am. J. Physiol. Endocrinol. Metab 2005, 288:E187-E193.
2. Bao S., Cao Y., Fan C., Fan Y., Bai S., Teng W., et al. Epigallocatechin gallate improves insulin signaling by decreasing toll-like receptor 4 (TLR4) activity in adipose tissues of high-fat diet rats. Mol. Nutr. Food Res 2014, 58:677-686.
3. Boden G. Obesity and free fatty acids. Endocrinol. Metab. Clin. North Am 2008, 37:635-646.
4. Boden G., She P., Mozzoli M., Cheung P., Gumireddy K., Reddy P., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005, 54:3458-3465.
5. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-e158.
6. Calder P.C., Ahluwalia N., Brouns F., Buetler T., Clement K., Cunningham K., et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr 2011, 106(Suppl. 3):S5-S78.
7. Cao H., Sekiya M., Ertunc M.E., Burak M.F., Mayers J.R., White A., et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013, 17:768-778.
8. Engl J., Ciardi C., Tatarczyk T., Kaser S., Laimer M., Laimer E., et al. A-FABP - a biomarker associated with the metabolic syndrome and/or an indicator of weight change?. Obesity 2008, 16:1838-1842.
9. Fain J.N. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm 2010, 2010:513948.
10. Fisher R.M., Eriksson P., Hoffstedt J., Hotamisligil G.S., Thorne A., Ryden M., et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia 2001, 44:1268-1273.
11. Furuhashi M., Hotamisligil G.S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov 2008, 7:489-503.
12. Furuhashi M., Tuncman G., Gorgun C.Z., Makowski L., Atsumi G., Vaillancourt E., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
13. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol 2010, 316:129-139.
14. Hertzel A.V., Bennaars-Eiden A., Bernlohr D.A. Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J. Lipid Res 2002, 43:2105-2111.
15. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
16. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
17. Hotamisligil G.S., Johnson S.R., Distel J.R., Ellis R., Papaioannou E.V., Spiegelman M.B. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
18. Hui X., Li H., Zhou Z., Lam K.S., Xiao Y., Wu D., et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J. Biol. Chem 2010, 285:10273-10280.
19. Jiao P., Ma J., Feng B., Zhang H., Diehl J.A., Chin Y.E., et al. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKbeta pathways. Obesity 2011, 19:483-491.
20. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation. Best Pract. Res. Clin. Endocrinol. Metab 2005, 19:547-566.
21. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
22. Lehmann F., Haile S., Axen E., Medina C., Uppenberg J., Svensson S., et al. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg. Med. Chem. Lett 2004, 14:4445-4448.
23. Libinaki R., Heffernan M., Jiang W.-J., Ogru E., Ignjatovic V., Gianello R., et al. Effects of genetic and diet-induced obesity. IUBMB Life 1999, 48:109-113.
24. Nguyen M.T., Satoh H., Favelyukis S., Babendure J.L., Imamura T., Sbodio J.I., et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem 2005, 280:35361-35371.
25. Nilsson C., Raun K., Yan F.F., Larsen M.O., Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol. Sin 2012, 33:173-181.
26. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol 2011, 11:85-97.
27. Pandey S. Hybridoma technology for production of monoclonal antibodies. Int. J. Pharm. Sci. Rev. Res 2010, 1:88-94.
28. Park S.E., Rhee E.J., Lee W.Y., Kim W.J., Yoo S.H., Bae J.C., et al. The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines. Nutr. Metab. Cardiovasc. Dis 2012, 22:525-532.
29. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9793-9798.
30. Pierre N., Deldicque L., Barbé C., Naslain D., Cani P.D., Francaux M. Toll-like receptor 4 knockout mice are protected against endoplasmic reticulum stress induced by a high-fat diet. PLoS ONE 2013, 8:e65061.
31. Ragheb R., Medhat A.M. Mechanisms of fatty acid-induced insulin resistance in muscle and liver. J. Diabetes Metab 2011, 2:127.
32. Rasouli N., Kern P.A. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab 2008, 93:S64-S73.
33. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
34. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest 2006, 116:3015-3025.
35. Storch J., Thumser A.E. The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta 2000, 1486:28-44.
36. Sulsky R., Magnin D.R., Huang Y., Simpkins L., Taunk P., Patel M., et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg. Med. Chem. Lett 2007, 17:3511-3515.
37. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6:307-319.
38. Terra X., Quintero Y., Auguet T., Porras J.A., Hernandez M., Sabench F., et al. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur. J. Endocrinol 2011, 164:539-547.
39. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
40. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
41. Tuncman G., Erbay E., Hom X., De Vivo I., Campos H., Rimm E.B., et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6970-6975.
42. Vernia S., Cavanagh-Kyros J., Barrett T., Jung D.Y., Kim J.K., Davis R.J. Diet-induced obesity mediated by the JNK/DIO2 signal transduction pathway. Genes Dev 2013, 27:2345-2355.
43. Wang Y., Liu D., Zhao H., Jiang H., Luo C., Wang M., et al. Cordyceps sinensis polysaccharide CPS-2 protects human mesangial cells from PDGF-BB-induced proliferation through the PDGF/ERK and TGF-beta1/Smad pathways. Mol. Cell. Endocrinol 2014, 382:979-988.
44. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest 2003, 112:1785-1788.
45. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem 2006, 52:405-413.
46. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
47. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest 2003, 112:1821-1830.
48. Yang R., Castriota G., Chen Y., Cleary M.A., Ellsworth K., Shin M.K., et al. RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice. Int. J. Obes 2011, 35:217-225.
49. Zhang M., Zhu W., Li Y. Small molecule inhibitors of human adipocyte fatty acid binding protein (FABP4). Med. Chem 2014, 10:339-347.
50. Zhang X., Xu A., Chung S.K., Cresser J.H., Sweeney G., Wong R.L., et al. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes 2011, 60:486-495.
51. Zimmerman A.W., Veerkamp J.H. New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci 2002, 59:1096-1116.